Mild stroke and rapidly improving symptoms: it's not always a happy ending.

摘要

Despite the substantial benefit of intravenous recombinant tissue-type plasminogen activator (IV rtPA) in improving neurologic outcomes in acute ischemic stroke (AIS) patients, only about half of those patients who arrive at the hospital in time receive it. In 2009, 3.4% to 5.2% of AIS patients in the United States received thrombolytics, approximately double the rate of treatment in 2005, Rapid recognition and transport and quick treatment in the Emergency Department are clear goals for further improving treatment rates.